Genmab
1,322
DKK
-0.23 %
Less than 1K followers
GMAB
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
-0.23%
-17.27%
-11.42%
-10.98%
-17.63%
-36.5%
-44.15%
-1.56%
+3,776.83%
Genmab is a pharmaceutical company. The company specializes in the research and development of antibodies, which are mainly used in the treatment of cancer patients with lymphatic leukemia and solid tumors. Research and development are based on the company's own developed technology platform and operations are held on a global level. Genmab was founded in 1999 and is headquartered in Copenhagen, Denmark.
Read moreMarket cap
87.51B DKK
Turnover
145.04M DKK
Revenue
21.53B
EBIT %
31.14 %
P/E
10.82
Dividend yield-%
-
Financial calendar
8.5
2025
Interim report Q1'25
7.8
2025
Interim report Q2'25
6.11
2025
Interim report Q3'25
All
Research
Press releases
ShowingAll content types
Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
Capital Increase in Genmab as a Result of Employee Warrant Exercise
EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma
Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference
Notice to Convene the Annual General Meeting of Genmab A/S
Genmab Files Annual Report with the U.S. Securities and Exchange Commission
Genmab Publishes 2024 Annual Report
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024
Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference
